XML 220 R57.htm IDEA: XBRL DOCUMENT v3.22.1
Acquisition of Lucid (Narrative) (Details) - Lucid
1 Months Ended
Sep. 21, 2021
USD ($)
Share
$ / shares
shares
Disclosure of detailed information about business combination [line items]  
Consideration transferred, acquisition-date fair value $ 7,290,731
Ownership interest 4.50%
Acquisition related costs $ 128,320
Class B subordinate voting shares  
Disclosure of detailed information about business combination [line items]  
Consideration transferred, acquisition-date fair value $ 7,023,732
Issued on acquisition of net assets of Prismic Pharmaceuticals, Inc (shares) | shares 4,502,392
Share issue price per share | $ / shares $ 1.56
Number of instruments or interests issued or issuable | Share 304,880
Stock options  
Disclosure of detailed information about business combination [line items]  
Consideration transferred, acquisition-date fair value $ 196,436
Issued on acquisition of net assets of Prismic Pharmaceuticals, Inc (shares) | shares 161,091
Warrants  
Disclosure of detailed information about business combination [line items]  
Consideration transferred, acquisition-date fair value $ 70,563
Issued on acquisition of net assets of Prismic Pharmaceuticals, Inc (shares) | shares 112,162